D. E. Shaw & Co., Inc. Acumen Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.14 - $4.01 $117,714 - $220,578	55,007 New	55,007 $133,000
Q4 2023 Feb 14, 2024	BUY	$1.86 - $4.48 $256,733 - $618,369	138,029 New	138,029 $530,000
Q2 2023 Aug 14, 2023	SELL	$3.59 - $6.59 $357,937 - $657,049	-99,704 Reduced 62.23%	60,504 $291,000
Q1 2023 May 15, 2023	SELL	$3.75 - $6.65 $306,123 - $542,859	-81,633 Reduced 33.75%	160,208 $650,000
Q4 2022 Feb 14, 2023	BUY	$4.81 - $10.17 $371,327 - $785,113	77,199 Added 46.89%	241,841 $1.31 Million
Q3 2022 Nov 14, 2022	BUY	$4.44 - $10.48 $648,528 - $1.53 Million	146,065 Added 786.27%	164,642 $1.65 Million
Q2 2022 Aug 15, 2022	SELL	$3.08 - $4.88 $91,164 - $144,443	-29,599 Reduced 61.44%	18,577 $87,000
Q1 2022 May 16, 2022	BUY	$3.91 - $6.73 $82,145 - $141,390	21,009 Added 77.33%	48,176 $188,000
Q4 2021 Feb 14, 2022	BUY	$6.54 - $15.31 $57,898 - $135,539	8,853 Added 48.34%	27,167 $184,000
Q3 2021 Nov 15, 2021	BUY	$14.5 - $20.28 $265,553 - $371,407	18,314 New	18,314 $272,000

41.8M

57.7K

749K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $79.8M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.